地昔帕明                        
                
                                
                        
                            医学                        
                
                                
                        
                            免疫球蛋白E                        
                
                                
                        
                            药理学                        
                
                                
                        
                            免疫学                        
                
                                
                        
                            白细胞介素2受体                        
                
                                
                        
                            鼻腔给药                        
                
                                
                        
                            抗抑郁药                        
                
                                
                        
                            内科学                        
                
                                
                        
                            抗体                        
                
                                
                        
                            免疫系统                        
                
                                
                        
                            T细胞                        
                
                                
                        
                            海马体                        
                
                        
                    
            作者
            
                Y. Zhang,Hongtao Zhen,W. Yao,Fang Bian,Xiaobo Mao,Xiaohong Yang,Si Jin            
         
                    
        
    
            
            标识
            
                                    DOI:10.1177/039463201302600110
                                    
                                
                                 
         
        
                
            摘要
            
            Allergic rhinitis (AR) is characterized by IgE-mediated immediate hypersensitivity and usually progresses to chronic nasal inflammation, with depression as one of its comorbidities. The importance of treating the depression in AR patients has been increasingly recognized. Desipramine is a representative of tricyclic-antidepressant agents. In the present study we investigate whether desipramine has therapeutic effects on AR inflammation. BALB/C mice were sensitized by intraperitoneal injection of ovalbumin (OVA), followed by repeated challenge with OVA intranasally. Desipramine was administered orally to treat the mice. The nasal symptoms (sneezing, nasal scratching etc.) of AR were evaluated to determine the severity of AR. Cytokines in the nasal lavage fluid (NALF), including interferon-γ (IFN-γ), interleukin 4 (IL-4) and serum OVA-specific immunoglobulin E (IgE) antibody were measured by ELISA. The regulatory T cells (T reg ) and T helper cells 17 (T h 17) were quantified by flow cytometric analysis. As a result, the repeated oral administration of desipramine attenuated the nasal symptoms (sneezing and nasal rubbing) in AR mice. Desipramine also suppressed the serum OVA-specific IgE and IL-4 levels, but had no effect on IFN-γ level. Moreover, desipramine treatment up regulated CD4 + CD25 + Foxp3 + T reg cells, which were found down-regulated in established AR mice. Meanwhile, desipramine administration attenuated CD4 + IL-17 + T h 17 cells, which were significantly increased in AR mice. These results suggest that the antidepressant drug, desipramine, also has anti-allergic action, which was possibly achieved by reducing allergen-specific IgE and T h 2 cytokine production and maintaining a balance between T reg and T h 17 cells. Thus, this study provide the first evidence that desipramine may be utilized to treat allergic diseases, especially for those allergic patients with depression or depression patients with allergy.
         
            
 
                 
                
                    
                    科研通智能强力驱动
Strongly Powered by AbleSci AI